Shoshana M. Rosenberg, ScD, MPH; Michaela S. Tracy, BA; Meghan E. Meyer, BS; Karen Sepucha, PhD; Shari Gelber, MS, MSW; Judi Hirshfield-Bartek, MS; Susan Troyan, MD; Monica Morrow, MD; Lidia Schapira, MD; Steven E. Come, MD; Eric P. Winer, MD; Ann H. Partridge, MD, MPH
Financial Support: Dr. Partridge and the YWS receive support from Susan G. Komen for the Cure. Dr. Rosenberg receives support from the National Cancer Institute (NIH 5 R25 CA057711).
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-0924.
Reproducible Research Statement: Study protocol, statistical code, and data set: Available from Dr. Partridge (e-mail, firstname.lastname@example.org).
Requests for Single Reprints: Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, D1210, 450 Brookline Avenue, Boston, MA 02115.
Current Author Addresses: Dr. Rosenberg: Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 601, Boston, MA 02215.
Ms. Tracy, Ms. Meyer, and Ms. Hirshfield-Bartek: Dana-Farber Cancer Institute, 450 Brookline Avenue, L243, Boston, MA 02215.
Dr. Sepucha: Massachusetts General Hospital, 50 Staniford Street, S50-9, Boston, MA 02114.
Ms. Gelber: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Mailstop CLS-11007, 450 Brookline Avenue, Boston, MA 02215.
Dr. Troyan: Brigham and Women's Hospital, Department of Breast Surgical Oncology, 75 Francis Street, Boston, MA 02115.
Dr. Morrow: Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Avenue, New York, NY 10065.
Dr. Schapira: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114.
Dr. Come: Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Room CC-913, Boston, MA 02215.
Drs. Winer and Partridge: Dana-Farber Cancer Institute, 450 Brookline Avenue, Y12, Boston, MA 02215.
Author Contributions: Conception and design: M.S. Tracy, K. Sepucha, S. Gelber, M. Morrow, S.E. Come, A.H. Partridge.
Analysis and interpretation of the data: S.M. Rosenberg, M.S. Tracy, K. Sepucha, S. Troyan, L. Schapira, S.E. Come, A.H. Partridge.
Drafting of the article: S.M. Rosenberg, K. Sepucha, J. Hirshfield-Bartek, L. Schapira, A.H. Partridge.
Critical revision of the article for important intellectual content: S.M. Rosenberg, M.S. Tracy, K. Sepucha, S. Troyan, M. Morrow, L. Schapira, S.E. Come, A.H. Partridge.
Final approval of the article: S.M. Rosenberg, M.S. Tracy, K. Sepucha, S. Gelber, J. Hirshfield-Bartek, S. Troyan, M. Morrow, S.E. Come, E.P. Winer, A.H. Partridge.
Provision of study materials or patients: M.E. Meyer, K. Sepucha, S. Troyan, L. Schapira, A.H. Partridge.
Statistical expertise: S.M. Rosenberg, S. Gelber.
Obtaining of funding: A.H. Partridge.
Administrative, technical, or logistic support: M.S. Tracy, M.E. Meyer, K. Sepucha, A.H. Partridge.
Collection and assembly of data: S.M. Rosenberg, M.S. Tracy, M.E. Meyer, K. Sepucha, A.H. Partridge.
Rates of contralateral prophylactic mastectomy (CPM) have increased dramatically, particularly among younger women with breast cancer, but little is known about how women approach the decision to have CPM.
To examine preferences, knowledge, decision making, and experiences of young women with breast cancer who choose CPM.
8 academic and community medical centers that enrolled 550 women diagnosed with breast cancer at age 40 years or younger between November 2006 and November 2010.
123 women without known bilateral breast cancer who reported having bilateral mastectomy.
A 1-time, 23-item survey that included items related to decision making, knowledge, risk perception, and breast cancer worry.
Most women indicated that desires to decrease their risk for contralateral breast cancer (98%) and improve survival (94%) were extremely or very important factors in their decision to have CPM. However, only 18% indicated that women with breast cancer who undergo CPM live longer than those who do not. BRCA1 or BRCA2 mutation carriers more accurately perceived their risk for contralateral breast cancer, whereas women without a known mutation substantially overestimated this risk.
The survey, which was administered a median of 2 years after surgery, was not validated, and some questions might have been misinterpreted by respondents or subject to recall bias. Generalizability of the findings might be limited.
Despite knowing that CPM does not clearly improve survival, women who have the procedure do so, in part, to extend their lives. Many women overestimate their actual risk for cancer in the unaffected breast. Interventions aimed at improving risk communication in an effort to promote evidence-based decision making are warranted.
Susan G. Komen for the Cure.
Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, et al. Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer: A Cross-sectional Survey. Ann Intern Med. ;159:373–381. doi: 10.7326/0003-4819-159-6-201309170-00003
Download citation file:
Published: Ann Intern Med. 2013;159(6):373-381.
Breast Cancer, Cancer Screening/Prevention, Hematology/Oncology, Prevention/Screening.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use